



**OASMIA**  
**Q1 PRESENTATION**  
**SEPTEMBER 2019**

# Contents



## **Status of the Board's review**

Jörgen Olsson, Chairman of the Board



## **Q1 figures and business activities**

Sven Rohmann, interim CEO



## Status of the Board's review

- BoD has worked intensively since the EGM in March reviewing several issues
- Considerably more extensive than expected
- Consultation with external legal experts
- Several measures have been implemented and communicated



## Ongoing legal cases

- The so-called ownership dispute relates to a promissory note loan that Nexttobe provided to Oasmia as early as 2015. The dispute has involved the parties Oasmia, Arwidsro and MGC
- The dispute between Oasmia and Arwidsro was settled in July 2019
- The dispute between Oasmia and MGC persists. In July and August, MGC sought to initiate various lawsuits against Oasmia
- As previously communicated, Oasmia disputes these claims as unfounded.



## Ongoing legal cases cont'd

- In the year-end report, Oasmia booked the remaining part of the promissory note loan as debt of MSEK 80 in capital, with maturity date August 24, 2019.
  - In connection with the maturity date, Oasmia decided not to, in any part, pay MGC in cash. Oasmia has, and will assert, counterclaims that exceed this amount.
  - Oasmia will defend its interests in these matters before the court when necessary and will seek to claim compensation for all damages caused. Pending further litigation, the entire booked debt of MSEK 80 plus interest remains in Oasmia's books.
- 
- The claims for damages, i.e. class actions, which have been prepared in the US court on the basis of Oasmia's ADR program are not considered to cause any loss risk for Oasmia and have not resulted in any reservation.



## Review of intellectual property rights

- A review of intellectual property rights shows that Oasmia owns the patent portfolio that forms the basis for the company's operations. No ownership of any intellectual property rights is disputed.
- However, it is unclear why the national patent registers have not been updated with information on transfer of ownership to Oasmia from the registered owner Ardenia Investment Ltd - a company controlled by Oasmia's former chairman Julian Aleksov.
- The company's external advisers have begun their work to contact the relevant patent authorities to update registers so that Oasmia stands as the owner of the patents.



## Restructuring of AdvaVet

- In the year-end report, Oasmia explained its decision to restructure the subsidiary AdvaVet and postpone former plans of listing the subsidiary
- This review shows that AdvaVet's agreements with its former management and Board, approved by AdvaVet's former Chairman of the Board, are legally complicated, very costly and have long maturities. It is also noted that these agreements were not coherent with the credit line from Oasmia. Some of these liabilities have been sorted out, after the reporting period
- Overall, the AdvaVet cost structure is suboptimal. Oasmia's Board of Directors and management thus continue to work on the restructuring of AdvaVet
- During the past quarter, a new Board and management has been appointed in AdvaVet, which is now reviewing all value-creating alternatives for Oasmia in the field of veterinary oncology



**Q1 figures and business activities**  
Sven Rohmann, interim CEO



## Q1 figures

- Consolidated net sales amounted to TSEK 182 (128)
- Operating loss was TSEK 35,909 (26,572)
- Net loss after tax amounted to TSEK 39,928 (31,102)
- Loss per share was SEK 0.17 (0.18)
- Cash balance SEK 108.7 million as per July 31, 2019
- Total Equity SEK 428.1 million as per July 31, 2019



Q1 figures and  
business activities

# Corporate and business activities

- Organizational development and recruitment
- Strategic work with launch plan and business plan
- Market dialogue and presence
- Medical development and production



Q1 figures and  
business activities

# Organizational development and recruitment

- During and after the quarter, a number of recruitments were carried out on important positions in the company to get the leadership required in this upcoming phase of the company's development - to commercialize the company's products
- Hege Hellström and Anders Härfstrand, both with extensive biotech experience, nominated to become new Board members.

## **CEO (interim), Sven Rohmann**

– ex Novartis, Ganymed Pharmaceuticals, Merck-Serono. 32 years of pharma and oncology experience.

## **CBO and Deputy CEO, Anette Sjödin**

– ex Nestlé Skin Health, Pharmacia, Biacore. 30 years of biotechnology and life science experience.

## **CTO, Mikael Asp**

– 30 years of experience from several companies within the international pharmaceutical industry in R&D, production, quality assurance and as Qualified Person (QP).

## **CMO, Nina Heldring**

– more than 20 years of experience with pre-clinical and clinical medical research from renowned academic institutes and the pharmaceutical industry.

## **GM USA & Canada, Reinhard Koenig**

– ex Genentech, Boehringer Mannheim, Piramal Critical Care. More than 30 years of pharma and biotechnology experience.

## **CFO (acting), Joakim Lindén**

– more than 25 years of experience of change implementation in public and private limited companies in many industries, countries and roles, including as CFO.


## **GM Europe & Russia, Neil Yman**

– ex Pierre Fabre, Novartis, GSK and Roche. Over 17 years of pharma and oncology experience.



Q1 figures and  
business activities

## Business activities



Based on novel vitamin A derivative  
100% organic and vegan  
Compatible with all world religions



Clinical studies ✓  
Toxicological studies ✓  
Proof by market approval ✓



Improved solubility  
Allows for dual capsulation of  
soluble and non soluble API  
Combination of 2 therapies in one infusion



Patented until 2028 + SPC  
Every new combination is  
patentable for 20 years

SPC – supplementary protection certificate



Q1 figures and  
business activities

## Strategic work with launch plan and business plan

- Oasmia has a market approval in the EU for the indication ovarian cancer for Apealea - the company's first product based on XR17.
- Oasmia's first priority is to sell Apealea to the Nordic and European markets. A launch plan for Apealea and a business plan for the entire company is underway
- The dedicated Apealea launch team are producing market material for the launch next year
- The largest cancer market is the United States and the company's goal is to aim for an application for Apealea to the FDA in 2020



Q1 figures and  
business activities

## Market dialogue and presence

- During and after the first quarter, the new management team in Oasmia has met with a number of existing and potential partners both in and outside Europe to renew or create a dialogue
- The management has already or intend to participate in a number of industry events during the autumn, for example:

**BIOPHARM**  
AMERICA

Boston, USA, September 11-12

**ESMO** GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE

Barcelona, Spain, September 27-October 1

25<sup>TH</sup> ANNUAL INTERNATIONAL PARTNERING CONFERENCE  
**BIO-EUROPE**<sup>®</sup>  
NOVEMBER 11-13, 2019 // HAMBURG, GERMANY

Hamburg, Germany , November 11-13

11<sup>TH</sup> ANNUAL CONFERENCE  
**BIOTECH SHOWCASE**<sup>™</sup>

San Francisco, USA, January 13-15, 2020



Q1 figures and  
business activities

## Medical development and production

- In June, Oasmia presented the results of two clinical studies of the drug candidate Docecal in patients with metastatic breast cancer
- The results of the bioequivalence study with paclitaxel micellar in humans were published in the scientific journal "Advances in Therapy" in August.
- Publications is part of the company's strategy to make clinical data available to professionals in the industry.
- Oasmia's next step for the drug candidate Docecal is a part of the business and development plan for the entire company that is now in the works



**THANK YOU**